Tetrathiomolybdate

Generic Name: Tetrathiomolybdate

Drug Type: Small Molecule

Chemical Formula: MoS_₄

CAS Number: 16330-92-0

Unique Ingredient Identifier: 91U3TGV99T

Background: Tetrathiomolybdate is an oral, small-molecule, anticopper agent that is highly specific for lowering the levels of free copper in serum. COPREXA has completed pivotal clinical trials for the treatment of neurologic Wilson's disease. It is also developed for fibrotic disorders based upon the rationale that the fibrotic disease process is dependent upon the availability of free copper in the body.

Indication: Investigated for use/treatment in liver disease and pulmonary fibrosis.

Clinical Trials

Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants

Phase 1

Completed

Conditions: Wilson Disease

Interventions: Drug: Bupropion Hydrochloride
Drug: ALXN1840

First Posted Date: 2020-08-25

Last Posted Date: 2023-08-31

Lead Sponsor: Alexion Pharmaceuticals, Inc.

Target Recruit Count: 54

Registration Number: NCT04526210

Locations: 🇺🇸
Clinical Trial Site, Austin, Texas, United States

Phase 1 Study of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Participants.

Phase 1

Completed

Conditions: Wilson Disease

Interventions: Drug: ALXN1840
Drug: Celecoxib

First Posted Date: 2020-08-25

Last Posted Date: 2023-08-21

Lead Sponsor: Alexion Pharmaceuticals, Inc.

Target Recruit Count: 36

Registration Number: NCT04526197

Locations: 🇺🇸
Clinical Trial Site, Austin, Texas, United States

Copper Concentration & Histopathologic Changes in Liver Biopsy in Participants With Wilson Disease Treated With ALXN1840

Phase 2

Completed

Conditions: Wilson Disease

Interventions: Drug: Bis-Choline Tetrathiomolybdate

First Posted Date: 2020-06-09

Last Posted Date: 2024-10-18

Lead Sponsor: Alexion Pharmaceuticals, Inc.

Target Recruit Count: 31

Registration Number: NCT04422431

Locations: 🇬🇧
Research Site, London, United Kingdom

Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease

Phase 3

Terminated

Conditions: Wilson Disease

Interventions: Drug: SoC Therapy
Drug: ALXN1840

First Posted Date: 2018-01-18

Last Posted Date: 2024-06-17

Lead Sponsor: Alexion Pharmaceuticals, Inc.

Target Recruit Count: 214

Registration Number: NCT03403205

Locations: 🇬🇧
Research Site, London, United Kingdom

Efficacy and Safety Study of WTX101 (ALXN1840) in Adult Wilson Disease Patients

Phase 2

Completed

Conditions: Wilson Disease

Interventions: Drug: ALXN1840

First Posted Date: 2014-10-24

Last Posted Date: 2021-09-29

Lead Sponsor: Alexion Pharmaceuticals, Inc.

Target Recruit Count: 29

Registration Number: NCT02273596

Locations: 🇬🇧
Clinical Trial Site, Birmingham, United Kingdom

Phase I Study of Tetrathiomolybdate in Combination With Carboplatin/Pemetrexed in Metastatic Non-small Cell Lung Cancer

Phase 1

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Tetrathiomolybdate

First Posted Date: 2013-04-23

Last Posted Date: 2019-07-19

Lead Sponsor: University of Rochester

Target Recruit Count: 26

Registration Number: NCT01837329

Locations: 🇺🇸
University of Rochester, Rochester, New York, United States

Study Comparing Tetrathiomolybdate vs Standard Treatment in Primary Biliary Cirrhosis

Phase 3

Completed

Conditions: Primary Biliary Cirrhosis

Interventions: Other: Placebo
Drug: Tetrathiomolybdate

First Posted Date: 2008-12-10

Last Posted Date: 2017-05-23

Lead Sponsor: George Brewer

Target Recruit Count: 29

Registration Number: NCT00805805

Locations: 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States

Study of ATN-224 in Patients With Prostate Cancer

Phase 2

Conditions: Prostate Cancer

Interventions: Drug: ATN-224

First Posted Date: 2006-11-30

Last Posted Date: 2008-01-30

Lead Sponsor: Attenuon

Target Recruit Count: 50

Registration Number: NCT00405574

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 3 locations

Randomized Trial of ATN-224 and Temozolomide in Advanced Melanoma

Phase 2

Conditions: Melanoma

First Posted Date: 2006-10-04

Last Posted Date: 2007-12-06

Lead Sponsor: Attenuon

Target Recruit Count: 60

Registration Number: NCT00383851

Locations: 🇺🇸
Cancer Center of the Carolinas, Greenville, South Carolina, United States
🇺🇸
Hematology and Oncology Specialists, LLC, Metairie, Louisiana, United States
🇺🇸
Center for Cancer and Blood Disorders, Bethesda, Maryland, United States

and more 14 locations

Phase II Study of Tetrathiomolybdate (TM) in Patients With Breast Cancer

Phase 2

Terminated

Conditions: Breast Cancer

Interventions: Drug: Tetrathiomolybdate

First Posted Date: 2005-09-19

Last Posted Date: 2025-05-16

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 16

Registration Number: NCT00195091

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy